These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18816687

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Is there a threshold for the deleterious effect of smoking in Crohn's disease?
    Reddy RP, Tremaine WJ.
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S16-7. PubMed ID: 18816663
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Infliximab: how to use it in pediatric Crohn's disease.
    Ruemmele FM.
    J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):12-4. PubMed ID: 15187774
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Infliximab for Crohn's disease: more questions than answers.
    Freeman HJ.
    Can J Gastroenterol; 2001 Jun; 15(6):360-2. PubMed ID: 11429663
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M, Italian Multicentric Study Group on Infliximab.
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D.
    Rev Med Chir Soc Med Nat Iasi; 2010 Aug; 114(1):85-90. PubMed ID: 20509281
    [Abstract] [Full Text] [Related]

  • 18. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
    Kugathasan S.
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S40-3. PubMed ID: 11685975
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Successful use of infliximab for perianal Crohn's disease in pregnancy.
    Chaparro M, Gisbert JP.
    Inflamm Bowel Dis; 2011 Mar; 17(3):868-9. PubMed ID: 20564533
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.